No profile data available.
Alvotech (ALVO) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Luxembourg, Luxembourg, with about 1,279 full-time employees.
It reported revenue of $586.32 million for fiscal year 2025, up 19.7% from fiscal year 2024, and net income of $27.92 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $105.77 million, down 38.9% from a year before. Europe was its largest region in fiscal year 2025, with 52% of revenue. Its market capitalization was $2.06 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Alvotech reported $586.32 million in revenue for fiscal year 2025, up 19.7% from $489.68 million in fiscal year 2024. In Q2 2026 revenue was $105.77 million.
Europe: 52% of revenue by region in fiscal year 2025, followed by Usa (41%).
$2.06 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Kiniksa Pharmaceuticals International, plc (KNSA), Aurinia Pharmaceuticals Inc. (AUPH), Viridian Therapeutics, Inc. (VRDN), Zenas BioPharma, Inc. (ZBIO).